Список літератури, представлений в прототипі клінічної настанови 7 страница

719. Jacob S, Rett K, Henriksen EJ. Antihypertensive therapy and insulin sensitivity: do we have to redefine the role of beta-blocking agents? Am J Hypertens 1998;11:1258–1265. RV.

720. Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, Lubsen J, Lutiger B, Metra M, Remme WJ, Torp-Pedersen C, Scherhag A, Skene A. Carvedilol Or Metoprolol Euro­pean Trial Investigators. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003;362:7–13. RT.

721. Abuissa H, Jones PG, Marso SP, O’Keefe JH Jr. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials. J Am Coll Cardiol 2005;46:821–826. MA.

722. Rocchini AP. Obesity hypertension salt sensitivity insulin resistance. Nutr Metab Cardiovasc Dis 2000;10:287–294. RV.

723. Bakris G, Molitch M, Hewkin A, Kipnes M, Sarafidis P, Fakouhi K, Bacher P, Sowers J. STAR Investigators. Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care 2006;29:2592–2597.

724. Zillich AJ, Garg J, Basu S, Bakris GL, Carter BL. Thiazide diuretics potassium the development of diabetes: a quantitative review. Hyper­tension 2006;48:219–224. MA.

725. Van de Laar FA, Lucassen PL, Akkermans RP, Van de Lisdonk EH, De Grauw WJ. Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose. Cochrane Database Syst Rev 2006;4:CD005061. RV.

726. Kurtz TW, Pravenec M. Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin-angiotensin system. J Hypertens 2004;22: 2253–2261. RV.

727. Schupp M, Janke J, Clasen R, Unger T, Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 2004;109:2054–2057.

728. DREAM (Diabetes REduction Assessment with ramipril rosiglitazone Medication) Trial Investigators; Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, Hanefeld M, Hoogwerf B, Laakso M, Mohan V, Shaw J, Zinman B, Holman RR. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006; 368:1096–1105. RT.

729. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefebvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Koranyi L, Laakso M, Mokan M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J. PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglit Azone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366:1279–1289. RT.

730. Sarafidis PA, Nilsson PM. The effects of thiazolidinediones on blood pressure levels - a systematic review. Blood Press 2006;15:135–150. RV.

731. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S. RIO-Europe Study Group. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005; 365:1389–1397. RT.

732. Despres JP, Golay A, Sjostrom L. Rimonabant in Obesity-Lipids Study Group. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005;353:2121–2134. RT.

733. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J. RIO-North America Study Group. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 2006;295:761–775. RT.

734. Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF, RIO-Diabetes Study Group. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes. Lancet 2006;368:1160–1172. RT.

735. ClinicalTrials.gov.CRESCENDO: comprehensive rimonabant evaluation study of cardiovascular endopoints outcomes. December 2005: http// clinicaltrials.gov/. RT.

736. Deedwania P, Barter P, Carmena R, Fruchart JC, Grundy SM, Haffner S, Kastelein JJ, LaRosa JC, Schachner H, Shepherd J, Waters DD. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet 2006;368:919–928. RT.

737. Wing RR, Phelan S. Long-term weight loss maintenance. Am J Clin Nutr 2005;82 (1 Suppl):222S–225S. RV.

738. Cuspidi C, Macca G, Sampieri L, Michev I, Salerno M, Fusi V, Severgnini B, Meani S, Magrini F, Zanchetti A. High prevalence of cardiac and extra-cardiac target organ damage in refractory hypertension. J Hypertens 2001;19:2063–2070. OS.

739. Logan AG, Perlikowski SM, Mente A, Tisler A, Tkacova R, Niroumand M, Leung RS, Bradley TD. High prevalence of unrecognized sleep apnoea in drug-resistant hypertension. J Hypertens 2001;19:2271–2277. OS.

740. Parati G, Ongaro G, Bonsignore MR, Glavina F, Di Rienzo M, Mancia G. Sleep apnoea and hypertension. Curr Opin Nephrol Hypertens 2002; 11:201–214. RV.

741. Narkiewicz K, Wolf J, Lopez-Jimenez F, Somers VK. Obstructive sleep apnea and hypertension. Curr Cardiol Rep 2005;7:435–440. RV.

742. Baguet JP, Narkiewicz K, Mallion JM. Update on hypertension manage­ment: obstructive sleep apnea and hypertension. J Hypertens 2006; 24:205–208. RV.

743. Calhoun DA. Low-dose aldosterone blockade as a new treatment para­digm for controlling resistant hypertension. J Clin Hypertens 2007;9 (Suppl 1):19–24. RV.

744. Saha C, Eckert GJ, Ambrosius WT, Chun TY, Wagner MA, Zhao Q, Pratt JH. Improvement in blood pressure with inhibition of the epithelial sodium channel in blacks with hypertension. Hypertension 2005;46: 481–487. RT.

745. Lane DA, Shah S, Beevers DG. Low-dose spironolactone in management of resistant hypertension: a surveillance study. J Hypertens 2007;25: 891–894. OS.

746. Eide IK, Torjesen PA, Drolsum A, Babovic A, Lilledahl NP. Low-renin status in therapy-resistant hypertension: a clue to efficient treatment. J Hypertens 2004;22:2217–2226. OS.

747. de Leeuw PW, Kroon AA, Scheffers I, Tordoir J, Schmidli, Mohaupt M, Allemann Y, Jordan J, Engeli S, Liebeskind U, Luft FC, Eckert S, Hansky B, Kieval R, Cody R, Rossing M, Irwin E, Peters T. Baroreflex hyper­tension therapy with a cronically implanted system: preliminary efficacy and safety results from the rheos debut-ht study in patients with resistant hypertension. J Hypertens 2006;24(Suppl 4):S300. (abstract).

748. Isles CG. Malignant hypertension and hypertensive encephalophaty. In: Swales JD editor. Textbook of Hypertension. London: Blackwell Scienti­fic Publications; 1994. pp.1233–1248. RV.

749. Davis BA, Crook JE, Vestal RE, Oates JA. Prevalence of renovascular hypertension in patients with grade III or IV hypertensive retinopathy. N Engl J Med 1979;301:1273–1276. OS.

750. Lip GY, Beevers M, Beevers G. The failure of malignant hypertension to decline: a survey of 24 years’ experience in a multiracial population in England. J Hypertens 1994;12:1297–1305. OS.

751. Giese J. Acute hypertensive vascular disease, 2: Studies on vascular reaction patterns and permeability changes by means of vital microscopy and colloidal tracer technique. Acta Pathol Microbiol Scand 1964;62:497–515. OS.

752. Kincaid-Smith P, McMichael J, Murphy EA. The clinical cause and pathology of hypertension with papilloedema. Quart J Med 1958;27: 117–154. OS.

753. Isles CG, Liu KG, Boulton-Jones M, Cameron H, Lever AF, Murray G, Robertson JWK. Factors influencing mortality in malignant hyper­tension. J Hypertens 1985;3(Suppl 3):405–407. OS.

754. Lip GY, Beevers M, Beevers DG. Complications and survival of 315 patients with malignant-phase hypertension. J Hypertens 1995;13: 915–924. OS.

755. Gotto AM Jr. Review of primary and secondary prevention trials with lovastatin, pravastatin, and simvastatin. Am J Cardiol 2005;96: 34F–38F. RV.

756. Clearfield M. Statins and the primary prevention of cardiovascular events. Curr Atheroscler Rep 2006;8:390–396. RV.

757. Thavendiranathan P, Bagai A, Brookhart MA, Choudhry NK. Primary pre­vention of cardiovascular diseases with statin therapy: a meta-analysis of randomized controlled trials. Arch Intern Med 2006;166: 2307–2313. MA.

758. Gorelick PB, Schneck M, Berglund LF, Feinberg W, Goldstone J. Status of lipids as a risk factor for stroke. Neuroepidemiology 1997;16: 107–115. RV.

759. Heart Protection Study Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7–22. RT.

760. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Meinders AE, Norrie J, Packard CJ, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RG. PROSPER study group. PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002;360:1623–1630. RT.

761. Amarenco P, Bogousslavsky J, Callahan A 3rd, Goldstein LB, Hennerici M, Rudolph AE, Sillesen H, Simunovic L, Szarek M, Welch KM, Zivin JA. Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006;355:549–559. RT.

762. The ALLHAT Officers, Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002;288:2998–3007. RT.

763. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O’Brien E, Ostergren J. ASCOT investigators. The preven­tion of coronary events and stroke with atorvastatin in hypertensive subjects with average or below average cholesterol levels. The Anglo-Scandinavian Cardiac Outcomes Trial: Lipid Lowering Arm (ASCOT:LLA). Lancet 2003;361:1149–1158. RT.

764. Borghi C, Dormi A, Veronesi M, Immordino V, Ambrosioni E. Use of lipid-lowering drugs and blood pressure control in patients with arterial hypertension. J Clin Hypertens 2002;4:277–285. RV.

765. Kosoglou T, Statkevich P, Johnson-Levonas AO, Paolini JF, Bergman AJ, Alton KB. Ezetimibe: a review of its metabolism pharmacokinetics drug interactions. Clin Pharmacokinet 2005;44:467–494. RV.

766. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324: 71–86. MA.

767. Zanchetti A, Hansson L, Dahlof B, Julius S, Menard J, Warnold I, Wedel H. Benefit and harm of low-dose aspirin in well-treated hyper­tensives at different baseline cardiovascular risk. J Hypertens 2002; 20:2301–2307. CT.

768. Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, Leys D, Matias-Guiu J, Rupprecht HJ. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischae-mic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004;364:331–337. RT.

769. Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, Hennekens CH, Buring JE. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005;352:1293–1304. RT.

770. Hayden M, Pignone M, Phillips C, Mulrow C. Aspirin for the primary pre­vention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002;136: 161–172. MA.

771. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003;326:1419. RV.

772. Sanmuganathan PS, Ghahramani P, Jackson PR, Wallis EJ, Ramsay LE. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials. Heart 2001;85:265–271. MA.

773. Zanchetti A, Hansson L, Leonetti G, Rahn KH, Ruilope L, Warnold I, Wedel H. Low-dose aspirin does not interfere with the blood pressure-lowering effects of antihypertensive therapy. J Hypertens 2002;20: 1015–1022. RT.

774. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in non-diabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229–234. OS.

775. Stamler J, VaccaroO, Neaton JD, Wentworth D. Diabetes other risk-factors 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16:434–444. OS.

776. Knowler WC, Sartor G, Melander A, Schersten B. Glucose tolerance and mortality, including a substudy of tolbutamide treatment. Diabetologia 1997;40:680–686. OS.

777. Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes melli-tus. Atherosclerosis Risk in Communities Study. N Engl J Med 2000; 342:905–912. OS.

778. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837–853. RT.

779. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acar-bose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP- NIDDM trial. JAMA 2003;290:486–494. RT.

780. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multi-factorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348:383–393. RT.

781. The Diabetes Control, Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977–986. RT.

782. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B. Diabetes Control Complications Trial/Epidemiology of Diabetes Interventions Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643–2653. CT.

783. Balkau B, Shipley M, Jarrett RJ, Pyorala K, Pyorala M, Forhan A, Eschwege E. High blood glucose concentration is a risk factor for mor­tality in middle-aged nondiabetic men. 20-year follow-up in the White­hall Study, the Paris Prospective Study, and the Helsinki Policemen Study. Diabetes Care 1998;21:360–367. OS.

784. European Diabetes Policy Group 1999. A desktop guide to type 2 diabetes mellitus. Diabetes Med 1999;16:716–730. GL.

785. ADVANCE trial study group Rationale, design of the ADVANCE study: a randomised trial of blood pressure lowering, intensive glucose control in high-risk individuals with type 2 diabetes mellitus. Action in Diabetes and Vascular Disease: PreterAx and DiamicroN Modified-Release Controlled Evaluation. J Hypertens 2001;19(Suppl):S21–S28. RT.

786. Campos C, Segura J, Rodicio JL. Investigations in secondary hyper­tension: renal disease. In: Zanchetti A, Hansson L, Rodicio JL. editors, Hypertension. London: McGraw Hill International; 2001. pp. 119–126. RV.

787. Keane WF, Eknoyan G. Proteinuria albuminuria risk assessment detection elimination (PARADE): a position paper of the National Kidney Foun­dation. Am J Kidney Dis 1999;33:1004–1010. GL.

788. Koler H, Wandel E, Brunck B. Acanthocyturia – a characteristic marker for glomerular bleeding. Kidney Int 1991;40:115–120. OS.

789. Elliott WJ. Secondary hypertension: renovascular hypertension. In: Blackh & Elliott WG (eds). Hypertension: a Companion to Braunwald’s Heart Disease. Saunders Elsevier, 2007, pp. 93–105. RV.

790. Safian RD, Textor SC. Renal-artery stenosis. N Engl J Med 2001;344: 431–442. RV.

791. Krumme W, Blum U, Schwertfeger E, Fliigel P, Hollstin F, Schollmeyer P, Rump LC. Diagnosis of renovascular disease by intra-extrarenal Doppler scanning. Kidney Int 1996;50:1288–1292. OS.

792. Vasbinder BGC, Nelemans PJ, Kessels AGH, Kroon AA, De Leeuw PW, van Engelshoven JMA. Diagnostic tests for renal artery stenosis in patients suspected of having renovascular hypertension: a meta-analysis. Ann Intern Med 2001;135:401–411. MA.

793. Bruce GH. Intervention for renal artery stenosis: endovascular and sur­gical roles. J Hypertens 2005;23(Suppl 3):S23–S29. RV.

794. Aurell M, Jensen G. Treatment of renovascular hypertension. Nephron 1997;75:373–383. RV.

795. Plouin PF, Chatellier G, Darne B, Raynaud A. Blood pressure outcome of angioplasty in atherosclerotic renal artery stenosis: a randomized trial. Essai Multicentrique Medicaments vs Angioplastie (EMMA) Study Group. Hypertension 1998;31:823–829. RT.

796. Webster J, Marshall F, Abdalla M, Dominiczak A, Edwards R, Isles CG, Loose H, Main J, Padfield P, Russell IT, Walker B, Watson M, Wilkinson R. Randomised comparison of percutaneous angioplasty vs continued medical therapy for hypertensive patients with atheromatous renal artery stenosis. Scottish and Newcastle Renal Artery Stenosis Collaborative Group. J Hum Hypertens 1998;12:329–335. OS.

797. van Jaarsveld BC, Krijnen P, Pieterman H, Derkx FH, Deinum J, Postma CT, Dees A, Woittiez AJ, Bartelink AK, Man in ⁰tVeld AJ, Schalekamp MA. The effect of balloon angioplasty on hypertension in atherosclerotic renal-artery stenosis. Dutch Renal Artery Stenosis Inter­vention Cooperative Study Group. N Engl J Med 2000;342:1007–1014. OS.

798. Nordmann AJ, Woo K, Parkes R, Logan AG. Balloon angioplasty or medical therapy for hypertensive patients with atherosclerotic renal artery stenosis? A meta-analysis of randomized controlled trials. Am J Med 2003;114:44–50. MA.

799. Reisch N, Peczkowska M, Januszewicz A, Neumann HP. Pheochromo-cytoma: presentation diagnosis treatment. J Hypertens 2006;24: 2331–2339. RV.

800. Sawka AM, Jaeschke R, Singh RJ, Young WF Jr. A comparison of bio­chemical tests for pheochromocytoma: measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines. J Clin Endocrinol Metab 2003;88:553–558. OS.

801. Bravo EL. Evolving concepts in the pathophysiology diagnosis treatment of pheochromocytoma. Endocrine Rev 1994;15:356–368. RV.

802. Goldstein DS, Eisenhofer G, Flynn JA, Wand G, Pacak K. Diagnosis and localization of pheochromocytoma. Hypertension 2004;43:907–910. RV.

803. Sjoberg RJ, Simcic KJ, Kidd GS. The clonidine suppression test for pheo-chromocytoma. A review of its utility and pitfalls. Arch Intern Med 1992; 152:1193–1197. RV.

804. Ilias I, Pacak K. Current approaches and recommended algorithm for the diagnostic localization of pheochromocytoma. J Clin Endocrinol Metab 2004;89:479–491. RV.

805. Gimm O, Koch CA, Januszewicz A, Opocher G, Neumann HP. The genetic basis of pheochromocytoma. Front Horm Res 2004;31:45–60. RV.

806. Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C, Ganzaroli C, Giacchetti G, Letizia C, Maccario M, Mallamaci F, Mannelli M, Mattarello MJ, Moretti A, Palumbo G, Parenti G, Porteri E, Semplicini A, Rizzoni D, Rossi E, Boscaro M, Pessina AC, Mantero F. PAPY Study Investigators. A prospective study of the prevalence of primary aldosteronism in 1125 hypertensive patients. J Am Coll Cardiol 2006;48:2293–2300. OS.

807. Stowasser M, Gordon RD, Gunasekera TG, Cowley DC, Ward G, Archibald C, Smithers BM. High rate of detection of primary aldosteronism, including surgically treatable forms, after ‘non-selective’ screening of hypertensive patients. J Hypertens 2003;21: 2149–2157. OS.

808. Bravo EL, Tarazi RC, Dustan HP, Fouad FM, Textor SC, Gifford RW, Vidt DG. The changing clinical spectrum of primary aldosteronism. Am J Med 1983;74:641–651. RV.

809. Ganguly A. Primary aldosteronism. N Engl J Med 1998;339:1828–1834. RV.

810. Kaplan NM. The current epidemic of primary aldosteronism: causes and consequences. J Hypertens 2004;22:863–869. RV.

811. Gordon RD, Stowasser M, Tunny TJ, Klemm SA, Rutherford JC. High incidence of primary aldosteronism in 199 patients referred with hyper­tension. Clin Exp Pharmacol Physiol 1994;21:315–318. OS.

812. Lins PE, Adamson U. Plasma aldosterone-plasma renin activity ratio. A simple test to identify patients with primary aldosteronism. Acta Endo-crinol 1986;113:564–569. OS.

813. Pimenta E, Calhoun DA. Primary aldosteronism: diagnosis treatment. J Clin Hypertens 2006;8:887–893. RV.

814. Phillips JL, Walther MM, Pezzullo JC, Rayford W, Choyke PL, Berman AA, Linehan WM, Doppman JL, Gill JR Jr. Predictive value of preoperative tests in discriminating bilateral adrenal hyperplasia from an aldosterone-producing adrenal adenoma. J Clin Endocrinol Metab 2000;85:4526–4533. OS.

815. Bravo EL. Secondary Hypertension: Mineralocorticoid excess states. In: Black HR, Elliott WJ. editors Hypertension: A Companion to Braunwald’s Heart diseases. Amsterdam: Saunders-Elsevier; 2007. pp. 106–118. RV.

816. Krum H, Gilbert RE. Novel therapies blocking the renin-angiotensin-aldosterone system in the management of hypertension and related dis­orders. J Hypertens 2007;25:25–35. RV.

817. Newell-Price J, Bertagna X, Grossman AB, Nieman LK. Cushing’s syn­drome. Lancet 2006;367:1605–1617. RV.

818. Findling JW, Raff H. Cushing’s Syndrome: important issues in diagnosis management. J Clin Endocrinol Metab 2006;91:3746–3753. RV.

819. Strollo PJ Jr, Rogers RM. Obstructive sleep apnea. N Engl J Med 1996; 334:99–104. RV.

820. Lavie P, Herer P, Hoffstein V. Obstructive sleep apnoea syndrome as a risk factor for hypertension: population study. Br Med J 2000;320: 479–482. OS.

821. Grote L, Ploch T, Heitmann J, Knaack L, Penzel T, Peter JH. Sleep-related breathing disorder is an independent risk factor for systemic hypertension. Am J Respir Crit Care Med 1999;160: 1875–1882. OS.

822. Parati G, Bilo G, Lombardi C, Mancia G. Secondary hypertension: Sleep Apnea. In: Black HR, Elliott WJ. editors Hypertension: A companion to Braunwald’s Heart diseases. Amsterdam: Saunders-Elsevier; 2007. pp. 134–143. RV.

823. Australian National Health Medical Research Council Dietary Salt Study Management Committee. Fall in blood pressure with modest reduction in dietary salt intake in mild hypertension. Lancet 1989;i: 399–402. RT.

824. Port K, Palm K, Viigimaa M. Daily usage and efficiency of remote home monitoring in hypertensive patients over a one-year period. J Telemed Telecare 2005;11(Suppl 1):34–36. OS.

825. Kearney PM, Whelton M, Reynolds K, Whelton PK, He J. Worldwide prevalence of hypertension: a systematic review. J Hypertens 2004; 22:11–19. RV.

826. Burt VL, Cutler JA, Higgins M, Horan MJ, Labarthe D, Whelton P, Brown C, Roccella EJ. Trends in the prevalence awareness treatment control of hypertension in the adult US population. Data from the Health Examination Surveys 1960 to 1991. Hypertension 1995;26: 60–69. OS.

827. Amar J, Chamontin B, Genes N, Cantet C, Salvador M, Cambou JP. Why is hypertension so frequently uncontrolled in secondary prevention? J Hypertens 2003;21:1199–1205. OS.

828. Mancia G, Ambrosioni E, Agabiti-Rosei E, Leonetti G, Trimarco B, Volpe M. Blood pressure control and risk of stroke in untreated and treated hypertensive patients screened from clinical practice: results of the ForLife study. J Hypertens 2005;23:1575–1581. OS.